Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spike Glycoprotein S1 Receptor Binding Domain (RBD) of SARS-CoV-2 (RBD)
- Target
- RBD
- Molecular classification
- Glycoprotein, Viral protein, Receptor Binding Domain
01
Overview
The receptor-binding domain (RBD) is a critical part of the S1 subunit of the SARS-CoV-2 spike glycoprotein. It directly interacts with the human ACE2 receptor, mediating viral entry into host cells. Due to its exposed location and key role in infection, the RBD is a major target for neutralizing antibodies and is used in vaccines and diagnostic assays. Mutations within the RBD can affect ACE2 binding affinity, antibody recognition, and viral transmissibility and pathogenicity. Key mutations include N501Y, T478K, Q493R, and Q498R.
- Other names
- SARS-CoV-2 RBDSpike RBDS1 RBD
02
Mechanism of action
Binds to ACE2 receptor on host cells, initiating viral entry. Neutralizing antibodies block ACE2 binding.
03
Biological functions
Viral entryACE2 receptor bindingImmune evasion
04
Disease associations
InfectionCOVID-19Viral pathogenesis
05
Safety considerations
Immune escape due to mutationsPotential for antibody-dependent enhancement (ADE) with certain antibodies
06
Interacting drugs
Neutralizing antibodies
2 more in the full profile.
07
Biomarkers
Anti-RBD antibody titerRBD mutations (for variant identification)
Beyond the preview
Go deeper on Spike Glycoprotein S1 Receptor Binding Domain (RBD) of SARS-CoV-2 (RBD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spike Glycoprotein S1 Receptor Binding Domain (RBD) of SARS-CoV-2 (RBD).